Drug Profile
Research programme: RSV fusion inhibitors - Johnson and Johnson/Tibotec
Alternative Names: TMC-353121Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development; Tibotec BVBA
- Developer Janssen Research & Development
- Class
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in Europe (IV)
- 03 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the Pharmacokinetics and Viral Infections pharmacodynamics sections
- 03 Oct 2006 Preclinical development for Respiratory syncytial virus infections in Europe